Peter P. Mueller

Peter P. Mueller

Auto-generated profile, based on publicly available information

Peter P. Mueller

Merck

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
PMPeter P. Mueller
Peter P. Mueller
QCQiushi Chen
Qiushi Chen
TATurgay Ayer
Turgay Ayer
GNGizem S. Nemutlu
Gizem S. Nemutlu
AHAli Hajjar
Ali Hajjar
JCJagpreet Chhatwal
Jagpreet Chhatwal

2 January 2025 in Journal of Medical Economics
Verified
Journal Article
Open access
PMPeter P. Mueller
Peter P. Mueller
ATAtsushi Tajima
Atsushi Tajima
KCKelsie Cassell
Kelsie Cassell
TMTaizo Matsuki
Taizo Matsuki
NCNicole Cossrow
Nicole Cossrow
KOKwame Owusu-Edusei
Kwame Owusu-Edusei
This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach. A Markov model was employed to simulate the movement of the Japanese population among 4 health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae (PMS), and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level. Pneumococcal serotype distribution and vaccine effectiveness, as well as direct and indirect treatment costs and health-related utilities, were derived from published sources. The model used a lifetime horizon and 2% discounting of costs and life-years. Costs were adjusted to 2023 values in Japanese yen (¥). Outcomes were cases and deaths, life-years and quality-adjusted life-years (QALYs), vaccination and treatment costs, and incremental cost-effectiveness ratios (ICERs). The range over which V116 was cost-saving and cost-effective was determined. Compared to PCV20, V116 averted an additional 28 cases of IPD, 918 cases of NBPP, 5 deaths from IPD, and 51 deaths from NBPP over the lifetime of a single age 65 cohort. Life-years and QALYs gained were 1,019 and 642, respectively, relative to PCV20; V116 saved ¥733 million in direct medical costs and ¥557 million in indirect costs, compared to PCV20. V116 was found to be cost-saving at price premiums up to ¥1,322 (payer perspective) or ¥2,327 (societal perspective) and remained below a willingness-to-pay threshold of ¥5 million/QALY for premiums up to ¥7,113 (payer perspective) or ¥8,117 (societal perspective). V116 is projected to provide more population health benefits in Japan than PCV20, and to be cost-effective at a variety of price premiums.

31 May 2022 in Pancreatology
Verified
Journal Article
Closed access
MPMary Linton B Peters
Mary Linton B Peters
AEAndrew Eckel
Andrew Eckel
ALAnna Lietz
Anna Lietz
CSClaudia Seguin
Claudia Seguin
PMPeter Mueller
Peter Mueller
PPPari V. Pandharipande
Pari V. Pandharipande

5 October 2026 in Expert Review of Vaccines
Verified
Journal Article
Open access
MSMuloongo Simuzingili
Muloongo Simuzingili
PMPeter P. Mueller
Peter P. Mueller
LOLisa M. Oexle
Lisa M. Oexle
MLMarion de Lepper
Marion de Lepper
ZYZinan Yi
Zinan Yi
KOKwame Owusu-Edusei
Kwame Owusu-Edusei
1. S. pneumoniae is a gram-positive bacterium with over 100 distinct serotypes, defined by differences in polysaccharide capsule proteins [1].Approximately one-third of pneumococcal serotypes cause...

5 September 2026
Verified
Conference Paper
Closed access
PMPeter Mueller
Peter Mueller
MSMuloongo Simuzingili
Muloongo Simuzingili
SFSilvia Fernández-Soberón
Silvia Fernández-Soberón
MMMario Monterrubio
Mario Monterrubio
ZYZinan Yi
Zinan Yi
SSSilvia Fernández Soberón
Silvia Fernández Soberón
Introduction: PCV21 is a new 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [generated from deOAc-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any previously licensed pneumococcal vaccine. This study used the delta-price approach to conduct a cost-effectiveness analysis (CEA) of vaccinating adults aged 65+ years with PCV21 vs. PCV20 in Spain. Methods: A previously published Markov model, built to track the lifetime health and economic outcomes of using PCV21 compared to PCV20 among adults, was adapted to Spain. Parity in vaccine efficacy was assumed for shared serotypes. Vaccination coverage rates of 52%, 75%, or 82% were used for low-risk, at-risk, or high-risk individuals, respectively. Costs were adjusted to 2024 euros and a 3% discount rate for both costs and quality-adjusted life-years (QALYs). The CEA was conducted from the healthcare perspective. A premium delta-price for PCV21 (i.e., price difference vs. PCV20 below which PCV21 is cost-effective at a given willingness to pay per QALY) was used in the analysis. Results: Vaccinating adults aged 65+ years with PCV21 prevented an additional 93,700 combined cases of pneumococcal disease (PD) and 11,839 disease-related deaths beyond that of PCV20. When compared to PCV20, PCV21 yielded an additional 30,199 QALYs and reduced medical costs by 365 million euros. PCV21 was cost-saving up to a price of 59.42 € per dose above PCV20. At an ICER of 30,000 € per QALY gained, PCV21 was cost-effective up to a price of 206.77 € per dose above PCV20. Conclusions: PCV21 prevented considerably more PD cases and deaths than PCV20. The reduction in medical costs allows for a significant price premium at which PCV21 can be either cost-effective or even cost-saving.

5 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
PMPeter P. Mueller
Peter P. Mueller
MSMuloongo Simuzingili
Muloongo Simuzingili
IMIan Matthews
Ian Matthews
ZYZinan Yi
Zinan Yi
KOKwame Owusu-Edusei
Kwame Owusu-Edusei
Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Methods: A published Markov model was used to simulate a single-cohort of vaccine-naïve adults who became eligible for age-based vaccination at age 65 years, with uptake occurring over time. The cohort was followed until a maximum age of 100 years. Model inputs were derived from publicly available national health data and published reports. Outcomes were discounted at 3.5% annually, and costs were adjusted to the 2024 Great Britain Pound (£). Additional analyses explored the impact of changing the age-based recommendation from 65 years to 75 years. Scenarios involving instantaneous vaccine uptake rates were included as part of the sensitivity analyses. A deterministic sensitivity analysis was performed on the incremental direct medical costs between vaccinating with aPCV21 vs PCV20 under the age-based recommendation of 65 years. Results: Using an age-based recommendation of 65 years, aPCV21 led to fewer cases, deaths, and costs than PCV20. Compared with PCV20, aPCV21 averted an additional 138 IPD cases, 1 PMS case, and 22 IPD deaths, saving £1.2 million in direct medical costs. Raising the age-based recommendation from 65 to 75 years and using aPCV21 (or PCV20, respectively), resulted in 120 (92) additional IPD cases, 2 (1) additional PMS case(s), 19 (14) additional IPD death(s), and an extra £1.1 (£0.8) million in direct medical costs. The deterministic sensitivity analysis showed that aPCV21 reduced direct medical costs across all parameter ranges. Conclusions: Compared with PCV20, aPCV21 prevented more IPD cases, IPD deaths, and direct medical costs among older adults in the UK. Changing the age-based recommendation from age 65 to 75 resulted in worse health and economic outcomes.